|
Re: FDA approves Subcutaneous Herceptin for her2+ Breast Cancer
Given subcutaneously by nurse. Average visit 5 minutes. No loading dose required. No modification of dose for body weight required. Given every 3 weeks. Not to be administered by patient themselves. Cost savings comes from less facility, nurse time.
Popular in rest of world.
Available in April, perhaps as soon as April 1. Whether insurance will reimburse /when as yet undetermined. Genentech urged providers to utilize their access
program in the interim
|